| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2014088519 |
| Title |
Compounds Including Map Kinase Interacting Kinases 1 and 2 (Mnk1 and Mnk2) Modulators and Abl and Abl (T315I) Inhibitors, and Uses Thereof. |
| Abstract |
The present invention relates to certain piperazine-based compounds that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b and/or as ABL or ABL (T315I) inhibitors. The invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of cancer, inflammatory and Alzheimer disease conditions, as well as methods of treatment of these disorders. |
| Applicant(s) |
Agency for Science, Technology and Research |
| Representative Drug(s) |
D0ZH4I |
Drug Info
|
IC50 < 500 nM |
[1] |
| Patent ID |
WO2013068909 |
| Title |
N-Methyl-2-[3-((E)-2-Pyridin-2-Yl-Vinyl)-1H-Indazol-6-Ylsulfanyl]-Benzamide for The Treatment of Chronic Myelogenous Leukemia. |
| Abstract |
The present invention relates to a method of treating chronic myelogenous leukemia in a subject comprising administering to the subject a compound, such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, that inhibits the T315I mutation in BCR-ABL tyrosine kinase, or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition comprising a compound such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]- benzamide, that inhibits the T315I mutation in BCR-ABL tyrosine kinase, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. |
| Applicant(s) |
Pfizer Inc |
| Representative Drug(s) |
D0MX5B |
Drug Info
|
IC50 = 0.418 nM |
[1] |
